Your browser doesn't support javascript.
loading
Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial.
Conforti, Fabio; Zucali, Paolo Andrea; Pala, Laura; Catania, Chiara; Bagnardi, Vincenzo; Sala, Isabella; Della Vigna, Paolo; Perrino, Matteo; Zagami, Paola; Corti, Chiara; Stucchi, Sara; Barberis, Massimo; Guerini-Rocco, Elena; Di Venosa, Benedetta; De Vincenzo, Fabio; Cordua, Nadia; Santoro, Armando; Giaccone, Giuseppe; De Pas, Tommaso Martino.
Afiliación
  • Conforti F; Division of Melanoma, Sarcomas, and Rare Tumors, European Institute of Oncology, IRCCS, Milan, Italy; Department of Medical Oncology, Cliniche Humanitas Gavazzeni, Bergamo, Italy. Electronic address: fabio.conforti@gavazzeni.it.
  • Zucali PA; Department of Biomedical Sciences, Humanitas University, Milan, Italy; Department of Oncology, IRCCS Humanitas Research Hospital, Milan, Italy.
  • Pala L; Division of Melanoma, Sarcomas, and Rare Tumors, European Institute of Oncology, IRCCS, Milan, Italy; Department of Medical Oncology, Cliniche Humanitas Gavazzeni, Bergamo, Italy.
  • Catania C; Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy.
  • Bagnardi V; Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy.
  • Sala I; Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy.
  • Della Vigna P; Division of Interventional Radiology, European Institute of Oncology, IRCCS, Milan, Italy.
  • Perrino M; Department of Oncology, IRCCS Humanitas Research Hospital, Milan, Italy.
  • Zagami P; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy.
  • Corti C; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy.
  • Stucchi S; Division of Melanoma, Sarcomas, and Rare Tumors, European Institute of Oncology, IRCCS, Milan, Italy.
  • Barberis M; Division of Pathology, European Institute of Oncology, IRCCS, Milan, Italy.
  • Guerini-Rocco E; Division of Pathology, European Institute of Oncology, IRCCS, Milan, Italy.
  • Di Venosa B; Division of Pathology, European Institute of Oncology, IRCCS, Milan, Italy.
  • De Vincenzo F; Department of Oncology, IRCCS Humanitas Research Hospital, Milan, Italy.
  • Cordua N; Department of Oncology, IRCCS Humanitas Research Hospital, Milan, Italy.
  • Santoro A; Department of Biomedical Sciences, Humanitas University, Milan, Italy; Department of Oncology, IRCCS Humanitas Research Hospital, Milan, Italy.
  • Giaccone G; Weill Cornell Medical Center, New York, NY, USA.
  • De Pas TM; Division of Melanoma, Sarcomas, and Rare Tumors, European Institute of Oncology, IRCCS, Milan, Italy; Department of Medical Oncology, Cliniche Humanitas Gavazzeni, Bergamo, Italy.
Lancet Oncol ; 23(10): 1287-1296, 2022 10.
Article en En | MEDLINE | ID: mdl-36096156
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Timoma / Neoplasias del Timo / Polimiositis Tipo de estudio: Clinical_trials / Guideline Límite: Adolescent / Humans Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Timoma / Neoplasias del Timo / Polimiositis Tipo de estudio: Clinical_trials / Guideline Límite: Adolescent / Humans Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article